|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, Timp3-deficient mice (Timp3<sup>-/-</sup>) are highly resistant to developing HCC in response to a diethylnitrosamine (DEN); therefore, we aimed to elucidate the biological role of genetic loss of Timp3 in obesity-related hepatocarcinogenesis.
|
31292722 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.
|
28751722 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reduced protein expression of TIMP-3 was associated with reduced tumor differentiation (P=0.003) and increased metastatic activity (P=0.005) in HCC cell lines.
|
27222429 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we found that inhibition of miR-21 in murine HMGB1-overexpressing HCC xenografts led to reduced tumor MMP activity through released repression of the miR-21 targets RECK and TIMP3, which ultimately impeded tumor progression.
|
25720799 |
2015 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, gene polymorphisms of TIMP-3 -1296 T>C (rs9619311) and TIMP-4 -55 T>C (rs3755724) play a role in the susceptibility of HCC among Taiwan women.
|
24903383 |
2014 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that TIMP-3 expression is a valuable prognostic biomarker for HCC and that TIMP-3 expression suggests a favorable prognosis for HCC patients.
|
25171061 |
2014 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated gene therapy targeting hepatocellular carcinoma (HCC) using the herpes simplex virus thymidine kinase/ganciclovir (HSVtk/GCV) suicide gene system and the tissue inhibitor of metalloproteinase 3 (Timp3) gene.
|
23598435 |
2013 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression and depletion of miR-181b showed that miR-181b enhanced matrix metallopeptidases (MMP)2 and MMP9 activity and promoted growth, clonogenic survival, migration and invasion of hepatocellular carcinoma (HCC) cells that could be reversed by modulating TIMP3 level.
|
20023698 |
2010 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A recombinant expression vector, which contained full-length cDNA of human TIMP-3, was constructed and transfected into the human hepatocarcinoma cell line HCC-7721 by the lipofectamine technique.
|
17897911 |
2007 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We found that SYK, E-cadherin, and TIMP-3 genes were methylated in 27%, 27%, and 42% of HCC neoplastic tissues, respectively.
|
17121887 |
2006 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
COX-2, p16, RASSF1A, and TIMP-3 were not methylated in LC and CH from patients without concurrent HCC.
|
14507645 |
2003 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results demonstrate the potential efficacy of repeated treatment of secreted TIMP-2 and TIMP-3 for the design of nonviral gene therapy for hepatocarcinoma.
|
12768188 |
2003 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant methylation in the HCC samples was detected in 71% of samples for p16, 25% for TIMP3, 17% for PTEN, 13% for CDH1, and 7% for RARbeta2.
|
12660822 |
2003 |